Nice timing for glitazones

Clifford J. Bailey; Caroline Day; Andrew J. Krentz

doi:10.1177/14746514030030051001

Nice timing for glitazones

Clifford J. Bailey^*
, Caroline Day
, Andrew J. Krentz

^*Corresponding author for this work

College of Health and Life Sciences

Aston University
Southampton General Hospital
Diabetes Research Group

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

The National Institute for Clinical Excellence (NICE) recently revised its guidance on the use of thiazolidinediones (TZDs). Days later, the European Agency for the Evaluation of Medicinal Products (EMEA) announced licence changes for TZDs that supersede the NICE guidance. The EMEA has approved TZDs for monotherapy if metformin is contraindicated or not tolerated. This article summarises the latest changes surrounding the use of TZDs in the UK.

Original language	English
Pages (from-to)	366-367
Number of pages	2
Journal	British Journal of Diabetes and Vascular Disease
Volume	3
Issue number	5
DOIs	https://doi.org/10.1177/14746514030030051001
Publication status	Published - 1 Sept 2003

Keywords

EMEA
NICE
Pioglitazone
Rosiglitazone
Thiazolidinediones

Access to Document

10.1177/14746514030030051001

Cite this

@article{2502467b02674cb08aacb37ff3163763,

title = "Nice timing for glitazones",

abstract = "The National Institute for Clinical Excellence (NICE) recently revised its guidance on the use of thiazolidinediones (TZDs). Days later, the European Agency for the Evaluation of Medicinal Products (EMEA) announced licence changes for TZDs that supersede the NICE guidance. The EMEA has approved TZDs for monotherapy if metformin is contraindicated or not tolerated. This article summarises the latest changes surrounding the use of TZDs in the UK.",

keywords = "EMEA, NICE, Pioglitazone, Rosiglitazone, Thiazolidinediones",

author = "Bailey, \{Clifford J.\} and Caroline Day and Krentz, \{Andrew J.\}",

year = "2003",

month = sep,

day = "1",

doi = "10.1177/14746514030030051001",

language = "English",

volume = "3",

pages = "366--367",

journal = "British Journal of Diabetes and Vascular Disease",

issn = "1474-6514",

publisher = "SAGE",

number = "5",

}

TY - JOUR

T1 - Nice timing for glitazones

AU - Bailey, Clifford J.

AU - Day, Caroline

AU - Krentz, Andrew J.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - The National Institute for Clinical Excellence (NICE) recently revised its guidance on the use of thiazolidinediones (TZDs). Days later, the European Agency for the Evaluation of Medicinal Products (EMEA) announced licence changes for TZDs that supersede the NICE guidance. The EMEA has approved TZDs for monotherapy if metformin is contraindicated or not tolerated. This article summarises the latest changes surrounding the use of TZDs in the UK.

AB - The National Institute for Clinical Excellence (NICE) recently revised its guidance on the use of thiazolidinediones (TZDs). Days later, the European Agency for the Evaluation of Medicinal Products (EMEA) announced licence changes for TZDs that supersede the NICE guidance. The EMEA has approved TZDs for monotherapy if metformin is contraindicated or not tolerated. This article summarises the latest changes surrounding the use of TZDs in the UK.

KW - EMEA

KW - NICE

KW - Pioglitazone

KW - Rosiglitazone

KW - Thiazolidinediones

UR - https://www.scopus.com/pages/publications/0242351186

UR - https://journals.sagepub.com/doi/pdf/10.1177/14746514030030051001

U2 - 10.1177/14746514030030051001

DO - 10.1177/14746514030030051001

M3 - Article

AN - SCOPUS:0242351186

SN - 1474-6514

VL - 3

SP - 366

EP - 367

JO - British Journal of Diabetes and Vascular Disease

JF - British Journal of Diabetes and Vascular Disease

IS - 5

ER -

Nice timing for glitazones

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this